ProPhase Labs, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
ProPhase Labs, Inc. (PRPH) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$4.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-06-01
- ProPhase Labs, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$4.91M.
- ProPhase Labs, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$7.38M.
- ProPhase Labs, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$4.79M, a 199.52% decline from fiscal 2022.
- ProPhase Labs, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was $4.81M, a 290.50% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$4.91M 10-K · filed 2026-06-01 | |
| 2024-12-31 | -$7.38M 10-K · filed 2026-06-01 | |
| 2023-12-31 | -$4.79M 10-K · filed 2025-04-01 | |
| 2022-12-31 | $4.81M 10-K · filed 2024-03-29 | |
| 2021-12-31 | $1.23M 10-K · filed 2023-03-29 | |
| 2020-12-31 | -$377.00K 10-K · filed 2022-03-31 | |
| 2019-12-31 | -$660.00K 10-K · filed 2021-03-31 | |
| 2018-12-31 | -$341.00K 10-K · filed 2020-03-26 | |
| 2017-12-31 | $14.51M 10-K · filed 2019-03-26 | $14.52M 10-K · filed 2018-03-28 |
| 2016-12-31 | -$975.00K 10-K/A · filed 2018-08-20 | |
| 2015-12-31 | -$1.22M 10-K/A · filed 2018-08-20 | -$1.26M 10-K · filed 2016-03-29 |
| 2014-12-31 | -$2.66M 10-K · filed 2017-02-24 | |
| 2013-12-31 | $138.00K 10-K · filed 2016-03-29 | |
| 2012-12-31 | -$661.00K 10-K · filed 2015-03-27 | |
| 2011-12-31 | -$925.00K 10-K · filed 2014-03-27 | |
| 2010-12-31 | -$1.20M 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |